REGEN
Get REGENGet Now
LibraryToolsNotesBlogFAQ

SS-31 (Elamipretide) Dosage and Protocols

SS-31 (Elamipretide) dosage protocols reported in published research, plus reconstitution and storage.

RE
Compiled from published research · Last updated 2026-07-24T00:00:00.000Z

Approved vs. Research Dosing

The FDA-approved Barth syndrome regimen uses a pre-filled subcutaneous formulation dosed daily; research-vendor protocols commonly cite around 40mg subcutaneous daily from a reconstituted vial, mirroring the approved dose. Outside the approved indication, there's no validated dose-finding data to guide use.

Reported protocol doses

Standard dose40 mg
Frequency1x daily
Routessubcutaneous

Reconstitution

A 40mg vial with 2mL of bacteriostatic water is the pairing reported most often. Research-vendor convention: 40mg vial reconstituted with 2mL bacteriostatic water. The FDA-approved Barth syndrome product is a pre-filled subcutaneous formulation, not a lyophilized research vial.

Work out your own concentration with the reconstitution calculator.

Doses shown are those reported in published research, not a recommendation.

References

  1. Elamipretide in Barth syndrome (TAZPOWER) · 2024
  2. MMPOWER-3 elamipretide trial · 2020
All SS-31 (Elamipretide) sections

Thymosin Alpha-1

longevity & healthspanAgrade

A 28-amino-acid thymic peptide approved in 35+ countries as Zadaxin for immune support — but never FDA-approved in the United States.

Oxytocin

longevity & healthspanBgrade

A naturally occurring nonapeptide — FDA-approved as Pitocin for labor, and separately studied off-label (intranasal) for social bonding and stress research.

Humanin

longevity & healthspanCgrade

A mitochondrial-derived peptide discovered protecting neurons from Alzheimer's-linked toxicity — cell and rodent data only, no human trial exists.

Put the whole protocol
in one place.

Download nowGet Now